Skip to main content
SpringerLink
Log in

Interplay Between CYP3A-Mediated Metabolism and Polarized Efflux of Terfenadine and Its Metabolites in Intestinal Epithelial Caco-2 (TC7) Cell Monolayers

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. To further characterize cytochrome P450 (CYP) and P-glyco-protein (Pgp) expression in monolayers of the Caco-2 cell clone TC7, a cell culture model of the human intestinal epithelium. To study the interplay between CYP3A and Pgp as barriers to intestinal drug absorption in TC7 cells using terfenadine and its metabolites as substrates.

Methods. mRNA expression of eight CYPs and Pgp was investigated in TC7 and parental Caco-2 (Caco-2p) cell monolayers using RT-PCR. The CYP3A kinetics was determined in microsomes from both cell lines. The transport, metabolism and efflux of terfenadine and its metabolites were investigated in TC7 monolayers.

Results. Both TC7 and Caco-2p cells expressed mRNA for Pgp and several important CYPs. However, mRNA for CYP3A4 was detectable only from TC7 cells. The relative affinity of CYP3A for terfenadine metabolism in the two cell lines was comparable, but the maximum reaction rate in the TC7 cells was 8-fold higher. The rate of transport of terfenadine and its metabolites hydroxy-terfenadine (HO-T) and azacyclonol across TC7 monolayers was 7.1-, 3.5- and 2.1-fold higher, respectively, in the basolateral to apical direction than it was in the apical to basolateral (AP-BL) direction. Inhibition studies indicated that the efflux was mediated by Pgp. Ketoconazole increased the AP-BL transport terfenadine dramatically by inhibiting both terfenadine metabolism and Pgp efflux.

Conclusions. Cell culture models such as TC7 provide qualitative information on drug interactions involving intestinal CYP3A and Pgp.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. L. S. Kaminsky, and M. J. Fasco. Small intestinal cytochrome P450. Toxicology 21:407-422 (1992).

    Google Scholar 

  2. A. P. Li, D. L. Kaminski, and A. Rasmussen. Substrates of human hepatic cytochrome P450 3A4. Toxicology 104:1-8 (1995).

    PubMed  Google Scholar 

  3. W. Chi-Yuan, L. Z. Benet, M. F. Hebert, S. K. Gupta, M. Rowland, D. Y. Gomez, and V. J. Wacher. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporin. Clin. Pharmacol. Ther. 58:492-497 (1995).

    PubMed  Google Scholar 

  4. K. E. Thummel, D. O'Shea, M. F. Paine, D. D. Shen, K. L. Kunze, J. D. Perkins, and G. R. Wilkinson. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59:491-502 (1996).

    PubMed  Google Scholar 

  5. V. J. Wacher, C.-Y. Wu, and L. Z. Benet. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implication for drug delivery and activity in cancer chemotherapy. Carcinogenesis 13:129-134 (1995).

    Google Scholar 

  6. A. H. Schinkel, U. Mayer, E. Wagenaar, C. A. Mol, L. van Deemeter, J. J. Smit, M. A. van der Valk, A. C. Voordouw, H. Spits, O. van Tellingen, J. M. Zijlmans, W. E. Fibbe, and P. Borst. Normal viability and altered pharmaceutics in mice lacking mdrl-type (drug-transporting) P-glycoproteins. Med. Sci. 94:4028-4033 (1997).

    Google Scholar 

  7. A. Sparreboom, J. van Asperen, U. Mayer, A. H. Schinkel, J. W. Smit, D. K. Meijer, P. Borst, W. J. Nooijen, J. H. Beijnen, and O. van Tellingen. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Pharmacology 94:2031-2035 (1997).

    Google Scholar 

  8. R. B. Kim, M. F. Fromm, C. Wandel, B. Leake, A. J. Wood, D. M. Roden, and G. R. Wilkinson. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:289-294 (1998).

    PubMed  Google Scholar 

  9. K. S. Lown, R. R. Mayo, A. B. Leichtman, H-L. Hsiao, K. Turgeon, P. Schmiedlin-Ren, M. B. Brown, W. Guo, S. J. Rossi, L. Z. Benet, and P. B. Watkins. Role of intestinal P-glycoprotein (mdrl) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62:248-260 (1997).

    PubMed  Google Scholar 

  10. R. Sandstrom, A. Karlsson, L. Knutson, and H. Lennernäs. Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm Res. 15:856-862 (1998).

    PubMed  Google Scholar 

  11. X. Boulenc, M. Bourrie, I. Fabre, C. Roque, H. Joyeux, Y. Berger, and G. J. Fabre. Regulation of cytochrome P450IA1 expression in a human intestinal cell line, Caco-2. J. Pharmacol Exp. Ther. 263:1471-1478 (1992).

    PubMed  Google Scholar 

  12. P. Schmiedlin-Ren, K. E. Thummel, J. M. Fisher, M. F. Paine, K. S. Lown, and P. B. Watkins. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1α, 25-dihydroxyvitamin D3. Mol. Pharmacol. 51:741-754 (1997).

    PubMed  Google Scholar 

  13. V. Carriere, T. Lesuffleur, A. Barbat, M. Rousset, E. Dussaulx, P. Costet, I. de Waziers, P. Beaune, and A. Zweibaum. Expression of cytochrome P450 3A in HT29-MTX cells and Caco-2 Clone TC7. FEBS Lett. 355:247-250 (1994).

    PubMed  Google Scholar 

  14. L. Gervot, V. Carriere, P. Costet, P-H. Cugnenc, A. Berger, P. H. Beaune, and I. de Waziers, CYP3A5 is major cytochrome P450 3A expressed in human colon and colonic cell lines. Environ. Toxicol. Pharmacol. 2:381-388 (1996).

    Google Scholar 

  15. S. D. Raeissi, Z. Guo G. L. Dobson P. Artursson, and I. J. Hidalgo. Comparison of CYP3A activities in a subclone of Caco-2 cells (TC7) and human intestine. Pharm. Res. 14:1019-1025 (1997).

    PubMed  Google Scholar 

  16. D. A. Garteiz, R. H. Hook, B. J. Walker, and R. A. Okerholm. Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneimittelforschung 32:1185-1190 (1982).

    PubMed  Google Scholar 

  17. K. T. Kirvisto, P. J. Neuronen, and U. Klotz. Inhibition of terfenadine metabolism: Pharmacokinetics and pharmacodynamic consequences. Clin. Pharmacokinet. 27:1-5 (1994).

    PubMed  Google Scholar 

  18. I. de Waziers, P. H. Cugnenc, C. S. Yang, J.-P. Leroux and P. H. Beaune. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther. 253:387-394 (1990).

    PubMed  Google Scholar 

  19. M. G. Mercurio, S. J. Shiff, R. A. Galbraith, and S. Sassa. Expression of cytochrome P450 mRNAs in the colon and the rectum in normal human subjects. Biochem. Biophys. Res. Commun. 210:350-355 (1995).

    PubMed  Google Scholar 

  20. J. Kolars, K. S. Lown, P. Schmiedlin-Ren, M. Ghosh, C. Fang, S. A. Wrighton, R. M. Merion, and P. B. Watkins. CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259 (1994).

    PubMed  Google Scholar 

  21. M. H. Gault, L. L. Longerich J. C. K. Lou, P. T. H. Ko, A. Fine, S. C. Vasdev, and M. A. Dawe. Digoxin biotransformation. Clin. Pharmacol. Ther. 35:74-82. (1984).

    PubMed  Google Scholar 

  22. B. Lacarelle, R. Rahmani, G. de Sousa, A. Durand, M. Placidi, and J. P. Cano. Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes. Fundam. Clin. Pharmacol. 5:567-582 (1991).

    PubMed  Google Scholar 

  23. H. Engman, H. Lennerns, and P. Artursson. Expression of cytochrome P450 3A4 and MDR1 in normal and transformed human intestinal epithelial cell lines. Pharm. Res. (supplement) 15:S6 (1998).

    Google Scholar 

  24. A. Zweibaum, H. P. Hauri, E. Sterchi, I. Chantret, K. Haffen, J. Bamat, and B. Sordat. Immunohistological evidence obtained with monoclonal antibodies, of small intestinal brush border hydrolases in human colon cancers and foetal colons. Int. J. Cancer 35:591-598 (1984).

    Google Scholar 

  25. W. N. Hait, J. F. Gesmonde, J. R. Murren, J. Yang, H. Chen, and M. Reiss. A new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem. Pharmacol. 45:401-406 (1995).

    Google Scholar 

  26. A. Seelig. A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. 251:252-261 (1998).

    PubMed  Google Scholar 

  27. J. Karlsson, S-M. Kuo, J. Ziemniak, and P. Artursson. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br. J. Pharmacol. 110:1009-1016 (1993).

    PubMed  Google Scholar 

  28. R. Sandstrom. Intestinal permeability and presystemic metabolism of R/S-verapamil and fluvastatin. Thesis 185, Uppsala University Library (1998).

  29. K. S. Lown, R. R. Mayo, A. B. Leichtman, H. L. Hsiao, D. K. Turgeon, R. P. Schmiedlin-Ren, M. B. Brown, W. Guo, S. J. Rossi, L. Z. Benet, and P. B. Watkins. Role of intestinal P-glycoprotein (mdrl) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62:248-260 (1997).

    PubMed  Google Scholar 

  30. T. J. Raub, C. L. Barsuhn, L. R. Williams, D. E. Decker, G. A. Swada, and N. F. Ho. Use of a biophysical-kinetic model to understand the roles of protein binding and membrane partitioning on passive diffusion of highly lipophilic molecules across cellular barriers. J. Drug Target. 1:269-286 (1993).

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Drug Metabolism and Pharmacokinetics, Rhone-Poulenc Rorer Central Research, Collegeville, Pennsylvania, 19426-0107

    Shamsi D. Raeissi & Ismael J. Hidalgo

  2. Division of Pharmaceutical Biochemistry, Uppsala University, Sweden

    Juan Segura-Aguilar

  3. Department of Pharmacy, Uppsala University, Sweden

    Shamsi D. Raeissi & Per Artursson

Authors
  1. Shamsi D. Raeissi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ismael J. Hidalgo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juan Segura-Aguilar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Per Artursson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Per Artursson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raeissi, S.D., Hidalgo, I.J., Segura-Aguilar, J. et al. Interplay Between CYP3A-Mediated Metabolism and Polarized Efflux of Terfenadine and Its Metabolites in Intestinal Epithelial Caco-2 (TC7) Cell Monolayers. Pharm Res 16, 625–632 (1999). https://doi.org/10.1023/A:1018851919674

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018851919674

Search

Navigation